article
Refining and targeting exatecan with ADC technology
DTR speaks with Dr Patrick van Berkel at ADC Therapeutics to discuss how the company is transforming exatecan delivery to achieve better health outcomes.
List view / Grid view
Target Molecule
article
New targeted therapies show promise in lung cancer treatment
Recent advancements in targeted therapies and immunotherapies are transforming lung cancer treatment. Discover how these innovations are improving outcomes and providing hope for patients.
article
Targeted protein degradation: turning undruggable targets into druggable targets
Targeted protein degradation (TPD) is a cutting-edge approach in drug discovery that offers a more precise and efficient way to alter cellular pathways, offering the capability to convert 'undruggable targets' into 'druggable targets.' In this article, Drug Target Review’s Izzy Wood interviewed Astellas’ Masahiko Hayakawa, Head of Targeted Protein Degradation,…
article
RNA processing in health and disease: challenges and opportunities of the field
In this interview, Sam Hasson, Senior Director at Rgenta Therapeutics, shares his journey in drug discovery, from graduate school to industry, and his current work developing small molecule therapeutics to target RNA processing. He discusses the challenges and opportunities in the field of RNA-centric drug discovery and highlights the potential…
whitepaper
Poster: Antibodies for microglial activation states
Development of novel rabbit monoclonal antibodies to characterise microglial activation states in murine models of Alzheimer’s disease.
news
Study reveals how hydroquinine kills major drug-resistant bacteria
Researchers say hydroquinine could be an effective weapon against a germ that can cause serious infections in humans, mostly hospital patients.
news
Discovery of two drugs could lead to earlier pancreatic cancer treatment
In pre-clinical studies, the University of Florida has identified two drugs that reverse ADM, a process that precedes pancreatic cancer.
whitepaper
Product hub: Targeted protein degradation – next-generation therapeutics
Helen Harrison, Director of Screening at Amphista Therapeutics, discusses targeted protein degradation (TPD) and the discovery of drugs in this area.
news
Researchers halt the growth of multiple myeloma in mice
Scientists from Stanford University have been able to halt the growth of multiple myeloma and diffuse large B cell lymphoma in mice with custom molecule sBCMA-Fc V3.
news
Molecular pathway shared by two neurodegenerative disorders found
Scientists have gained deeper knowledge about the mislocalisation of a protein, providing a possible therapeutic target that could have implications in treating dementia.
news
New platform screens for specific class of coronavirus antiviral compounds
Researchers developed a platform that can rapidly screen thousands of compounds to identify potential antiviral drugs to treat coronaviruses.
news
Key mechanism reveals how SARS-CoV-2 evades our immune system
Scientists have found that SARS-CoV-2 can knock out an important molecular pathway linked to an immune complex called MHC class I.
news
New target for overeating identified in the brain’s cerebellum
The study uncovered disordered signalling in the brain's cerebellum, offering a novel therapeutic target for Prader Willi syndrome.
news
New molecule could complement antibiotics to treat pneumonia
Scientists targeted a mouse's own cells using a synthetic molecule called EEZE, presenting a novel way to treat pneumonia.
news
Replication proteins a potential new target for COVID-19 vaccines
A new study claims that future COVID-19 vaccines should activate T cells to attack infected cells expressing replication proteins.
